Eosinophilic Inflammation Identifies Treatable Subtype of COPD
COPD patients with airway eosinophilia show stronger type 2 inflammation and respond well to inhaled corticosteroids, new research reveals.
Related Articles
Blood Test Offers Breakthrough in Heart Disease Treatment
A groundbreaking study has introduced a novel, image-based blood test that could significantly enhance the way doctors manage and personalise treatment for coronary artery disease…
COMy 2025: Infection Risk High with Bispecific Antibodies in Myeloma
New research from COMy 2025 reveals a high rate of infections among people with relapsed or refractory multiple myeloma receiving bispecific antibodies targeting CD3/BCMA and…
Transforming Rheumatology
Discover insights from Isabelle Amigues on the importance of hope in patient care and the inspiration behind starting her own practice.
Hema Now: Episode 17: What Drives Change in Leukaemia Cells?
Paolo Gallipoli, Clinical Reader, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London joins the podcast
Review of the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
THE 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held this year in the vibrant city of…
Minimal Residual Disease: Predicting and Preventing Relapse in Myeloma
In the evolving landscape of haematologic cancers, the concept of minimal residual disease, also known as measurable residual disease…
Subscribe to our email newsletter
Subscribe to receive our free quarterly newsletters, journal publication alerts, and other relevant content.
Breakthrough in Human Antibodies for Snakebite Treatment
Discover a study that utilised human antibodies to generate an effective treatment against snake venom. Learn more.
Oral Nutraceutical Shows Promise for Treating Acne
Discover a study that has highlighted the efficacy of an oral nutraceutical for treating acne vulgaris.
Argentina’s Maternal RSV Vaccine Shows Strong Early Impact
New findings provide compelling evidence for the protective benefits of maternal RSVpreF vaccination during pregnancy.